STOCKS TELEGRAPH

Author: ST Staff

  • VirTra Inc (VTSI) Establishes A Strategic Relationship With US Law Enforcements

    VirTra Inc (VTSI) is an American company that specializes in manufacturing and sale of emergency situation training simulators and weapon practice simulators for US Police, establishment, and for the use of the general public. The company sells simulators and various products across the globe through a supply chain force and has an international distribution network.

    The company provides a vast number of services that include fitting equipment, drilling for adequate use of simulators, limited undertakings, and related support. The company has a pro-rhetoric for force weaponry training and marksmanship firearms training for police, military or civilian use.

    VTSI has an extremely lucrative product line which includes simulators, upgrade components, the screenplay of different scripts related to real emergencies, scenario software, recoil kits, Threat fire, and other accessories. Vitra received a $1.5M order for federal law enforcement to provide resources for virtual training of the recruited staff and was also awarded $1.9M to support the air force research laboratory.

    VTSI stock surged after the company reported its 4th quarter result

    Shares of VirTra (VTSI) Soared in trading after the company announced its4th quarter results. The company’s earnings per share had an incredible increase of 600% in the past 52 weeks to $0.21, which beat the estimate of $0.04 by wall street analysts.

    Furthermore, the revenue of $6,566,000 sky-rocketed by 11.42% compared to the previous year, putting the company in a position of financial surplus. The 52-week high of the company ended at $6.09 with $2 being the company’s 52 week low. Vitra also received an order for 863,000 from the custom and border protection for simulation training products including new drop-in recoil kits.

    Vitra inc operates in the dynamic field of development, and commercialization of force training simulators, firearms training simulators, and driving simulators for law enforcement and civilian uses. Its long-term revenue growth and incredible increment of the stock price has proven to be a success after establishing a relationship with federal agencies, the military, and the general public.

  • Evolving Systems Inc. (EVOL) stock rises in the current market trading. Let’s find out why?

    Evolving Systems Inc. (EVOL) stock declined by 6.99% in the last trading close while the EVOL stock price is rising in the current market trading session. There is no recent news available related to this rise in EVOL stock price. Evolving Systems help Communications Service Providers (CSPs) to flourish in fast-changing, disruptive telecom environments. This is done by integrating Individuals, Systems, and Networks, allowing CSPs to enable, engage, and maintain their customers.

    Recent Past Events

    Quite recently on March 17, 2021, Evolving Systems reported its fourth quarter and full-year 2020 financial results. Given below is the summary:

    • EVOL has reported its full-year 2020 revenue as $26.4 million, this shows an increase of $0.6 million compared to the previous year. Whereas the revenue generated for the fourth quarter was $7.0 million, a rise of $0.3 million from the fourth quarter of 2019.
    • The operating income calculated for the full year 2020 was $1.0 million whereas for the fourth quarter it was $0.5 million.
    • Also, EVOL has managed to generate a positive cash flow from its operations in 2020.
    • Lastly, the positive adjusted EBTIDA for the fourth quarter of 2020 was $0.8 million whereas for the full year the adjusted EBTIDA was $2.4 million.

    Post Covid-19 Business Scenario

    Evolving Systems being a communication service provider has been bringing commerce to people through its connectivity technologies which in result makes its marketing ideas more relevant and valuable to use for the people and this definitely works to increase the revenue.

    Consumers had no choice but to curtail their activities due to initial government mandates of lockdowns and non-essential business restrictions. Many brick-and-mortar businesses were forced to reconsider their business models as a result, raising the investment profile of EVOL stock organically. Despite the fact that Covid-19 cases are decreasing, there are still serious concerns about mixing with the general public. It is assumed that contactless systems can maintain a lot of their utility until we can get back to normal. And under these circumstances, EVOL is one of the reliable service providers for people which makes it interesting for investors.

  • Moleculin Biotech, Inc. (MBRX) stock is popping high today. What’s going on?

    Moleculin Biotech, Inc. (MBRX) stock is popping high today. What’s going on?

    Moleculin Biotech, Inc. (MBRX) received the approval of Fast Track Designation for Annamycin by the FDA after which the MBRX stock happened to be green today. MBRX stock price saw an uptrend of 21.08% to reach $4.48 a share as of this writing. The MBRX stock was down with a 3.39 drop at the previous closing. Let’s have a look at current scenarios.

    A Brief look at Approval:

    Moleculin Biotech is mainly working on the treatment of tumors and viruses via the development of oncology drug products. Moleculin stock recently announced that it has got approval for fast-track designation for Annamycin, an anthracycline antibiotic, by the U.S. Food and Drug Administration. In connection with this approval, MBRX will now be able to review Annamycin results against the treatment of soft tissue sarcoma (STS) lung metastases. There are good chances for Moleculin to approve its product against STS lung metastases as well as acute myeloid leukemia.

    Why Annamycin is better?

    Approximately 130000 cases of Soft tissue sarcomas are reported annually around the globe and most of them are handled through the surgical procedure. Analysis shows that 20 to 50% of these cases metastasize to the lungs and once it happens, it then becomes more difficult to treat such cases. So far treatment is very limited for this condition due to severe cardiotoxicity effects by previously approved drugs. Annamycin on the other hand proved to be much effective so far as it does not cause severe cardiotoxicity in patients and hence better than the former drugs.

    Financial View  of MBRX stock

    Recently announced earnings results of RMBX stock show that Moleculin research and development surged to $12.8 million in 2020 as compared to $11.0 million in 2019 due to increased clinical trials that increased the operational costs. General and administrative costs were recorded at $6.8 million in 2020 while these were $6.3 million in 2019. An increase in these costs is mainly due to an increase in the staff but thanks to the COVID-19 that overall travel expenses were significantly reduced.

    Conclusion:

    MBRX stock is enjoying the bullish sentiment in the stock market in response to fast-track designation approval for Annamycin. Management is optimistic to receive early approval for its product in the future. Hence investors should do fundamental as well as technical analysis of MBRX stock before taking any decision.

  • Wave Life Sciences Ltd. (WVE) stock plunged in the pre-market trading session: here’s why

    Wave Life Sciences Ltd. (WVE) stock recently traded at $7.09 which is a 3.54% downward movement. The WVE stock previously closed at $7.35. It also plunged by 25.39%in the pre-market trading session at the time of writing.

    What caused the downward movement?

    The recent downward movement in WVE stock comes adjacent to the announcement by the clinical-stage company reporting that one of their genetic treatment programs has failed.

    Glimpse into WVE stock’s operational background

    Wave Life Sciences (WVE) is a clinical-stage medicines company that specifically focuses on genetics. Genetic medicines are aimed to provide treatment to patients that are ill with life-threatening diseases. WVE stock has a platform known as PRISM which is used for the development of drugs specifically related to oligonucleotides. These stereo pure oligonucleotides are analyzed, designed, optimized, and produced under the proprietary work on the PRISM platform. This will allow for the production of highly effective medicine among the therapeutic modalities that can target a broad range of genetically incurring diseases.

    What’s the news on the current Huntington disease-related program?

    One of the pipeline programs that Wave Life Sciences (WVE) focused on is the antisense oligonucleotide program. This was used to monitor the early-stage Huntington disease and the potential progress of two experimental drug candidates. The experimental drugs were known as WVE-120102 and WVE-120101. The latter drug was completed with dosing in the 32 mg cohort of the PRECISION-HD1 core trial. WVE stock announced that their study showed that WVE-120101 had little effect on reducing mutant Huntington protein during a dosing-period 8.1 monthly. For CSF, it had a non-statistically significant median reduction of 11.6% in mHTT compared to the pooled placebo group of 10%.

    The WVE-120102 similarly showed a non-statistically median reduction of 9.9% in mHTT compared to the pooled placebo group that had a median decrease in mHTT of 0.8%.

    Both experimental drug candidates failed to differentiate significantly the response from the placebo group and thus the effectiveness of the drug dosage to incur a response on mutant Huntington protein was menial. Each drug program will have a final follow-up visit for its test-subjects but there will be further administration of dosages as no observed changes in NfL and wtHTT were made.

    What’s next for the company?

    Wave Life Sciences Ltd. (WVE) along with the news of discontinuation of WVE-120101 and WVE-120102 has announced a focus on the development of the new clinical-trial program on its PRISM platform. The new program focuses on the experimental drugs WVE -003 and WVE-004.

    WVE-003 will be administered in Phase 1b/2a trial for which site activation and enrollment is being carried out. WVE-004 is still in the initial process of testing out the impact on key biomarkers and the safety of this drug.

    Clinical-stage healthcare companies always have numerous programs in their pipeline. Often these pipeline projects fail to produce the necessary and expected result in their trial-phases. This is why it is important for investors interested in biopharmaceutical and healthcare stocks to watch out for relevant news related to the progress or discontinuation of experimental treatment programs. Such news can significantly impact the movement of the stock and project the company’s overall outlook.

  • Why Aurora Mobile Limited (JG) stock is High today?

    Why Aurora Mobile Limited (JG) stock is High today?

    Aurora Mobile Limited (JG), a leading mobile application development service provider in China, announced the partnership agreement today with the world’s largest digital currency platform after which the JG stock price saw an uptrend of  9.93% to reach $4.43 a share at the time of this writing. JG stock was down at the previous trading session and a 5.18% drop was observed at closing. Let’s understand more of it.

    A look at the Recent Agreement:

    In connection with this partnership agreement, Aurora Mobile will help the platform through Artificial intelligence and analytics capabilities to make the platform more efficient and better in its operations and enhanced in user experience.JG’s management is focused on more advancement in the fields of Artificial intelligence and blockchain to maximize its value that it delivers to its customers in the future. The platform to which JG has partnered is expanded to more than 180 countries worldwide and provides services of cryptocurrencies spot and margin trading for major digital currencies like Bitcoin, ether, etc.

    Previous Agreements:

    Aurora stock has signed the agreement with Zuoyebang Education Technology (Beijing) Co., Ltd on March 25, 2021, pursuant to which the former would perform digital up-gradation and smart operation analytics to advance operational activities of later to increase the quality of Zuoyebang’s learning app. Zuoyebang’s App has more than 800 million registered users which shows that 7 out of 10 students had downloaded and used the app. Due to COVID-19, the conventional offline education system shifted to online which resulted in 170 million monthly and 50 million daily active users of the Zuoyebang App.

    On March 23, 2021, JG stock also entered into a partnership with  Koolearn Technology Holding Limited, a leading online education company, in order to provide push notification and smart operational analytics services. This partnership would help Koolearn in the advancement of its online education resources via AI technology.

    Financial View Of JG stock:

    In the fourth quarter of 2020, JG stock generated RMB106.0 million revenue with a 42% increase over the year while total revenue of the year 2020 was RMB471.6 million with a 48% decrease over the year. The gross profit of JG stock was RMB60.1 million in the fourth quarter of 2020 while its operating expenses reached MB106.5 million in the same period.

    Conclusion:

    Investors are responding to the Aurora stock in response to the partnership news. Thanks to the COVID-19 which created new opportunities for JG stock especially in the education industry. Fourth-quarter earnings results were satisfactory as compared to previous year results of the same period. Hence individuals need to keep an eye on this stock.

  • Color Star Technology Inc. (CSCW) stock surges during pre-market trading. Why is it so?

    Color Star Technology Inc. (CSCW) stock surges during pre-market trading. Why is it so?

    Color Star Technology Inc. (CSCW) stock plunged in the last trading close by 11.26% whereas the CSCW stock rises by 45.52% during the pre-market trading session after Color Star announced that they are building a non-fungible token (NFT) business. Color Star Technology is an entertainment and education business that offers online entertainment and also provides music education through online ways.

    What is happening?

    Color Star Technology recently revealed that its entirely owned subsidiary, Color China Entertainment, is establishing a non-fungible token (NFT) company for the manufacture, release, and promotion of NFT in the areas of network copyrights, concerts, artist images, TV shows, music, museum collections, and celebrity-exclusive product designs.

    Under this new initiative, NFT business by Color Star Technology will focus on Copyright procurement, concert videos, and ticket sales, as well as music and artist engagement. CSCW expects to capture more benefit and recognition opportunities for artists and collectors alike by using NFT encryption technology. Color Star’s latest NFT production could aid in the creation and launch of NFTs for all of the Color Star’s clients, including online museum collections, online concert videos and ticketing, personalized celebrity merchandise, and creator copyrights, to name a few.

    Recent Past Development

    On March 25, 2021, Color Star Technology announced that they have invited Steve Aoki who is among the world’s top 100 DJ stars to perform on Color Star App which is the international platform for sharing entertainment on April 23, 2021. Color Star is set to start its online live show which is expected to be a big hit. Steve Aoki is introducing his personal electronic music display to the Color Star APP for the first time, raising the appeal of electronic music. Steve Aoki will be the platform’s exclusive DJ for a month as part of this partnership.

  • Danimer Scientific Inc. (DNMR) stock declines in pre-market trading. Why is it happening?

    Danimer Scientific Inc. (DNMR) stock declined by 4.73% in the last trading close while the DNMR stock continued to decline by 11.56% in pre-market trading as well. The decline in DNMR stock price has been observed after Danimer Scientific announced its full-year 2020 financial results on March 29, 2021, in addition to few other developments in Danimer Scientific which we will discuss below. Danimer is a well-known company for its more eco-friendly and sustainable ways for making plastic products. Its renewable and safe biopolymers have been used to help produce biodegradable and compostable plastic goods that contribute to nature rather than polluting our lands and waters for more than a decade.

    Financial Results

    • The revenue generated by DNMR for the full year 2020 was $47.3 million which shows an increase of 46% compared to the revenue reported in the last year. The increase in revenue is due to the high demand increased PHA production capacity at the Company’s Winchester, Kentucky plant, which was brought online in 2020.
    • Net loss reported for the full year 2020 was $12.6 million including $4.3 million of transaction costs as well as professional fees which is linked with DNMR to become the private company.
    • DNMR has calculated its adjusted EBTIDA1 as $3.2 million which was $1.6 million in the prior year.
    • Adjusted EBITDAR1, which removes rent cost mainly related to DNMR’s Kentucky Facility and Georgia production activities, was $0.4 million, down from $1.5 million the year before.
    • Total debt outstanding of $56.6 million and cash of $377.6 million as of December 31, 2020, representing transaction gross proceeds from the Danimer-Live Oak merger completed in December 2020.
    • Lastly the Gross profit has also increased from $11.1 generated in the previous year to $11.5 million this time.

    Recent Development

    On March 29, 2021, DNMR announced that they are thinking of investing $700 million in extending their Bainbridge manufacturing activities, bringing their workforce in Decatur County to nearly quadruple. Danimer and Mars-Wrigley revealed a collaboration on March 16 to create revolutionary home compostable packaging which means SKITTLES will be the first brand to use the new packaging.

    Another recent news is that The Schall Law Firm which is a national shareholder rights litigation firm has announced that they are going to investigate the claims which are being made by the investors of Danimer Scientific. DNMR is being accused by its investors for violating the securities law. Quite possibly this recent news might have caused the DNMR stock price to decline since the investors are unhappy with them.

  • SRAX stock gains in Pre-Market: Let’s find out why

    SRAX stock announced its fourth quarter and full-year 2020 results after which the SRAX stock saw a boom of 17.39% to reach $5.40 a share in today’s pre-market at the time of this writing. SRAX stock also gained in the previous trading session and was up by 8.49% at closing. Let’s have a look at the financial results.

    Fourth-Quarter Results:

    SRAX stock marked $4.5 million revenue in the fourth quarter of 2020 which represents a whopping increase of 316% as compared to the same period in the previous year and a 74%  increase in comparison to the third quarter of 2020. Gross margin represents the growth of 73% while it was 44% in the same tenure of the prior year. Operating expenses were also increased in the fourth quarter to $5.3 million from $4.8 million in the fourth quarter of 2019.SRAX recorded a net income of $200K in the last three months of 2020 while it suffered a net loss of $4.4 million in the same period of last year.

    Fiscal Year 2020 Results:

    Revenue of SRAX stock reached $8.7M million in 2020 representing a surge of 141% over the year. Gross margins were moved from 53% in the prior year to 70% in 2020.$17.7 million Operating expenses were recorded in 2020 which represents a decrease of $2.1 million or 11%as compared to operating expenses of 2019.EBITDA in 2020 was -$8.4 million while it was -$15.5 million in 2019.Net income of SRAX for 2020 was -$14.7 million while it was -$16.9 in 2019.

    Financial Guidance of SRAX stock:

    SRAX projected its revenue for the fiscal year 2021 in the range of $23M – $25M while $7 million revenue for the second quarter of 2021 is estimated. Sequire, the SaaS platform of SRAX, has been gaining much popularity over time as 183 public companies bought its subscription of it. The subscription rate increased by 92% since SRAX released its third-quarter income of 2020.$16.5 million revenue of Sequire from the existing contracts in 2021 is recorded so far.

    In a Nutshell:

    SRAX stock has been hot among investors after the release of its positive financial results. SRAX Inc has shown significant progress over the year and it seems that momentum is already created for SRAX. Management is deeply focused on meeting the customer demand and adoption of new technologies. Hence SRAX stock can be a good bet for investors in the future.

  • Gritstone Oncology Inc. (GRTS) stock rises during after-hour trading. Let’s find out why?

    Gritstone Oncology Inc. (GRTS) stock rises during after-hour trading. Let’s find out why?

    Gritstone Oncology Inc. (GRTS) stock declined by 10.19% in the last trading closed while the GRTS stock rises by 11.35% during the after-hours trading session as Gritstone Oncology reported that the first individual has been medicated with its candidate COVID-19 vaccine in a Phase 1 trial as part of GRTS’s “CORAL” program. Gritstone Oncology, a clinical-stage biotechnology firm focuses on the development of immunotherapies to treat a variety of cancers and infectious diseases.

    What is happening?

    In a Phase 1 trial, the first person has been dosed under Gritstone’s “CORAL” program with its COVID-19 vaccine. The researchers are investigating the immunogenicity and protection of delivering SARS-CoV-2 viral antigens using their self-amplifying mRNA (SAM) and/or adenoviral vectors, which contain both Spike and other viral antigens not included in currently approved vaccines. The National Institute of Allergy and Infectious Diseases (NIAID) is funding the Phase 1 study, which is being carried out by their Infectious Diseases Clinical Research Consortium.

    In Phase 1 clinical trial which is a multicenter, open-label, dose- and age-escalation study in healthy adult participants to determine the immunogenicity and efficacy of Gritstone’s CORAL COVID-19 vaccine. In a parallel design, heterologous and homologous key vaccinations of the adenoviral vector and/or SAM vector representing SARS-CoV-2 Spike alone or Spike plus additional SARS-CoV-2 T cell epitopes are examined.

    Conclusion

    Gritstone through its CORAL program is expecting some visible results since it is considered as an efficient vaccine to counter the challenges faced by a coronavirus and also those which will possibly come out around novel Spike variants. Needless to say that COVID-19 is the most problematic thing that the world is going through for the past year and under such circumstances, GRTS bringing the efficient vaccine is definitely a remarkable achievement. Possibly due to this new positive development in Gritstone, the investors are making valuable investments in GRTS shares, Hence the GRTS stock price is rising in after-hours.

  • GSX Techedu Inc. (GSX) Stock Price Dipped An Alarming 62%. Here’s what happened

    GSX Techedu Inc. (GSX) stock price plunged approximately 19% on Monday. It had dropped 42% to close Friday’s market session, at $39.01, a price which lowered immensely in comparison with the previous days closing price. The stock price had significant fluctuation with the firm’s stock price losing62% within the last 5 trades.

    CEO of GSX Chen, lost an estimated $4.2B from his net worth dropping him from the Bloomberg Billionaire index of the richest 500 people on an international scale. The sales stimulated price variations for every stock encountering high-volume transactions and investors are also speculating force selling of stocks by a fund being liquidated. GSX, had block trading of 12.8 million shares offered at a discount to a price of $49.50, which was later closed at a ballpark figure of $39.

    Should You Keep An Eye Out For GSX

    GSX is selling 78% lower than its 52-week high, with the company reporting a gross margin of 75%. However short sellers slammed the company, implying that a large proportion of the users of the company are bots and software bugs. GSX financially recovered from this however, the company was degraded several times due to increased competition.

    Furthermore,a rumor that GSX corporate management is going to essentially diminish guidance for upcoming third-quarter earnings; and a loss of $135M is expected in their 3rd financial quarter has proven to be a huge downside for the company and has induced uncertainty in investor mindset.

    Conclusion

    GSX is a Chinese education technology company providing online tutoring services with a market capitalization of $9.54B. However, several rumors including an inflated balance sheet and the user of the websites being stated as ‘robots’ have made the company stock extremely volatile with the company plummeting immensely the last 5 trading sessions.